In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. CRISPR Therapeutics AG ...

Multisystemic smooth muscle dysfunction syndrome (MSMDS) is a rare condition associated with stroke, aortic dissection ...

Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic diseases. By ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced ...

Can genetic editing help improve the overall health of people living with type 1 diabetes? The results of a recent study ...

Researchers have unveiled a new type of nanostructure that dramatically improves CRISPR delivery. Called lipid nanoparticle ...

A study, published in the journal Frontiers in Genome Editing, outlines a method for editing single plant cells from sterile ...

This little company's scientific breakthrough opened up a whole new sliver of the drug market (although it's still leading the developmental race).

The global CRISPR-based gene editing market size is projected to grow from USD 4.46 billion in 2025 to over USD 13.39 billion by 2034, expanding at a CAGR of 13%. Growth is fueled by advancements in ...

Researchers engineered a bespoke CRISPR-Cas9 gene-editing enzyme to develop a potential therapy for MSMDS, which ...

It has long been understood that orchard automation is the key for industry’s profitability and sustainability. As part of ...

CRISPR Therapeutics CRSP and Beam Therapeutics BEAM are leading developers of therapies that utilize the Nobel Prize-winning CRISPR/Cas9 gene editing technology. While CRSP is the first and only ...